Dear MAPS members and supporters,
It’s easy to live in the present and quickly forget the past. As a result, the struggles and ultimately the accomplishments of those who worked to bring about social change are often lost to history.
MAPS Executive Director Rick Doblin, Ph.D., in the truncated summer edition of the MAPS Bulletin, reflects whether MAPS’ efforts to legitimize psychedelic psychotherapy will one day, and perhaps not far off, be taken for granted by society.
It’s a great question, and a sign of how far we have come in our path to mainstream psychedelic psychotherapy. Rick caught a glimpse of this shift already under way when he presented the results of our MDMA-assisted psychotherapy research to an audience at Kaiser Permanente Hospital in San Francisco last month. To the group of medical professionals, the challenge to conduct psychedelic research was almost old news. They, like us, were focused on the research and potential outcomes.
The days of outlawed psychedelic therapy are fleeting, but only due to the considerable support of MAPS members over the past 24 years.
Members should keep an eye out for Rick’s letter in the latest Bulletin, which should arrive in mailboxes in the coming days. If you are not a MAPS member, or are anxious to read about Michael Mithoefer, M.D. receiving a DEA Schedule 1 license to administer MDMA in our research or the events we are hosting this fall in New York, Boulder, Colorado, Los Angeles and the San Francisco Bay area, check out the Bulletin below linked to our webpage.
If you are not yet a MAPS member, consider becoming one today and put yourself in the vanguard of important social change. Whether you can give $25, $250 or $2,500, your gift will move us forward on our road to mainstreaming psychedelic psychotherapy.
Sincerely, Randolph Hencken, M.A. |
|
P.S. If you are MAPS member, we can always use additional support. One of the best ways to assist us is to enroll as a monthly contributor. Click on the Bulletin cover below to view the entire edition: |
|
![]() |
Share | Unsubscribe | MAPS Website | Join MAPS |